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in cellular membranes and accumulation in the plasma andChanges in conjugated linoleic acid and its metabolites in pa-
adipose tissue. The clinical significance of these changes re-tients with chronic renal failure.
mains to be investigated.Background. Conjugated linoleic acid (CLA) is a mixture
of isomers of linoleic acid with conjugated double bonds that
constitutes the most abundant fatty acid with conjugated dienes
(CDs) in humans. CLA, erroneously considered in the past as The conjugated diene (CD) structure (two doublea product of lipoperoxidation, has a dietary origin and has
bonds separated by a single bond) is unusual in polyun-shown to possess anticarcinogenic and anti-atherogenic activ-
saturated fatty acids (PUFAs) [1]. For many years, CDsity, mainly in animal studies. CLA can be metabolized to conju-
gated linolenic acid (CD18:3) and to conjugated eicosatrienoic have been considered as a marker of lipid peroxidation
acid (CD20:3) and these metabolites may be implicated in CLA because of the presence of the CD structure in PUFA
activity. Because of the presence of dyslipidemia and the high hydroperoxides, the primary products of lipid peroxida-incidence of cardiovascular and neoplastic diseases in uremic
tion [2–4]. However, it has been shown that the CDpatients, we evaluated CLA and its metabolites in these pa-
structure can also be formed during partial hydrogena-tients in order to evaluate their metabolism and site distribu-
tion. tion of fatty acids performed either industrially or by
Methods. We measured CLA, CD18:3, CD20:3, CD fatty anaerobic bacteria present in the rumen [1]. By this pro-
acid hydroperoxides (lipoperoxidation products), and linoleic cess, it has mainly formed the so-called conjugated lino-
acid in the plasma, adipose tissue, and red blood cell (RBC)
leic acid (CLA), which refers to a mixture of positionalmembranes by using high-pressure liquid chromatography in
and geometric isomers of linoleic acid with conjugatedthe following groups: (1) 23 chronic renal failure (CRF) pa-
tients with creatine clearance (CCr) .10 mL/min (26.2 6 16.7); double bonds. CLA constitutes by far the most abundant
(2) 21 end-stage CRF patients in conservative treatment with CD present in foods like ruminant’s meat, milk, and
CCr ,10 mL/min (6.8 6 1.8); (3) 30 hemodialysis (HD) patients; dairy products [5–7], and its presence in human tissues
and (4) 30 healthy controls. is not due to a lipoperoxidative process but to a dietaryResults. The incorporation of CLA, CD18:3, and CD20:3 in
origin [7].RBC membranes was significantly reduced in group 1 and
Conjugated linoleic acid is a cancer-preventive agent.was even more reduced in groups 2 and 3. CLA significantly
increased both in the plasma and adipose tissue of end-stage In animal models of chemical carcinogenesis, CLA has
CRF patients only. CD18:3 and CD20:3 did not change in the been shown to inhibit skin papilloma [8], forestomach
plasma and adipose tissue of any group. No significant changes neoplasia [9], mammary tumors [10, 11], and colon aber-in linoleic acid and CD fatty acid hydroperoxides were found.
rant crypt foci [12]. A recent epidemiological study inConclusions. The alterations of CD in CRF patients are not
Finland showed that a habitual consumption of wholedue to lipoperoxidation. The increased levels of CLA in plasma
and adipose tissue of end-stage CRF patients may be due either milk is associated with a reduced risk of breast cancer
to a reduced metabolization of CLA to CD18:3 and CD20:3, [13]. In another recent report, CLA protection against
or to an altered site distribution with reduced incorporation breast cancer was assessed by measuring its level in
breast adipose tissue as a reflection of the past CLA
dietary intake [14]. An inverse association between theKey words: fatty acids, linolenic acid, eicosatrienoic acid, hemodialysis,
end-stage renal disease, adipose tissue. CLA level and the risk of breast carcinoma was found,
suggesting a protective effect of CLA against breast can-Received for publication October 14, 1999
cer. The results of these two studies were at least consis-and in revised form February 9, 2000
Accepted for publication April 18, 2000 tent to hypothesize that CLA also may be effective in
humans.Ó 2000 by the International Society of Nephrology
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Besides the anticarcinogenic activity, it has also been chronic glomerulonephritis (28 cases), chronic pyelone-
phritis (4 cases), nephrosclerosis (18 cases), autosomalshown that CLA has an anti-atherogenic action [15], to
affect fat partitioning in the body [16, 17] and to normal- dominant polycystic kidney disease (15 cases), nephroli-
thiasis (2 cases), and unknown (7 cases).ize impaired glucose tolerance in the prediabetic Zucker
diabetic fatty (ZDF) rats [18]. Much less is known, how- Forty-four patients were on conservative treatment.
In these patients, the predicted creatinine clearance (CCr)ever, about the mechanism(s) whereby CLA exerts these
effects. One of the current hypotheses of CLA activity was calculated from serum creatinine according to Cock-
croff and Gault formula [27], and the mean value wasstems from its metabolism and influence on tissue lipid
metabolism [19]. In fact, we demonstrated in different 17.1 6 20.4 mL/min (range 3.6 to 51). The use of this
formula is known to be less accurate in end-stage renalexperimental models that CLA can be metabolized to
conjugated linolenic acid (CD18:3) and conjugated eico- failure. However, the attempt to use the equations re-
cently proposed by Walser, Drew, and Guldan presentedsatrienoic acid (CD20:3) [20, 21].
Although CLA has been detected in human tissues relevant pitfalls [28]; in fact, in some cases (older patients
with high serum creatinine levels), the result of the pre-[22], currently no data are available on CLA metabolites
in humans. In a previous article, we detected a higher dicted glomerular filtration rate was negative. In a previ-
ous study, we showed that total plasma CD increasedlevel of CD, with respect to controls, in the plasma and
adipose tissue of end-stage chronic renal failure (CRF) significantly only in advanced renal failure patients [23].
We found that the statistical discriminant CCr value waspatients [23]. However, the spectrophotometric method
used for CD detection in that study did not allow us to 10 mL/min. Similar results were found in this study con-
cerning the levels of plasma CLA. Therefore, nondia-separate the different types of CD fatty acids.
The increased incidence of neoplastic [24] and cardio- lyzed CRF patients were divided into two groups: pa-
tients with CCr .10 mL/min (range 10.1 to 51 mL/min,vascular diseases [25], together with the well-known dys-
lipidemia of uremic patients [26] and the availability mean 26.2 6 16.7, N 5 23) and patients with CCr ,10 mL/
min (range 3.6 to 10 mL/min, mean 6.8 6 1.8, N 5 21).of a new method to measure CLA and its metabolites
prompted us to evaluate them in lipids extracted from Thirty patients were on standard bicarbonate HD us-
ing substituted cellulosic or low-flux synthetic mem-plasma, adipose tissue, and red blood cell (RBC) mem-
branes of CRF patients at different stages of renal func- branes. The mean duration of dialysis treatment was
78.9 6 65.8 months (range 8 6 224). They were dialyzedtion impairment and of hemodialysis (HD) patients, in
order to evaluate CLA metabolism and site distribution. three times per week, and each session lasted four hours.
Blood flow was 300 to 450 mL/min, and dialysate flowIn addition, CD fatty acid hydroperoxides were also mea-
sured in the same samples in order to evaluate those was 500 mL/min. The ultrafiltration rate was 7 to 16
mL/min, and the dose of unfractionated standard heparinCDs of lipoperoxidation origin.
ranged from 2500 to 4500 IU per session.
Patients were chosen because of fistula placement/
METHODS
revision in the group of HD and CCr ,10 mL/min, in
Patients and controls order to obtain adipose tissue samples avoiding subcuta-
neous adipose tissue biopsies. In the group of patientsThe study was carried out on 74 CRF patients selected
from those attending the Division of Nephrology and with CCr .10 mL/min, only 4 patients out of 23 needed
fistula placement. The other 19 patients were recruitedDialysis of the University Hospital of Modena (Modena,
Italy). Thirty healthy control subjects were selected from from outpatients attending our division. In these pa-
tients, only blood samples were taken. Control subjectspatients who were admitted to the department of surgery
for carpal tunnel syndrome surgery. Exclusion criteria were chosen from those undergoing carpal tunnel syn-
drome surgery in order to have a sampling site similarfor both patients and controls included subjects with
systemic diseases such as diabetes mellitus, liver disorders, to that of the patients.
Dietary protein and phosphate intake were restrictedneoplasms, collagen-vascular diseases, smokers, plasma
total cholesterol or triglycerides higher than 250 mg/dL, in patients on conservative treatment. However, most of
the patients in the group with CCr .10 mL/min wereblood transfusions within six months prior to the study,
or history of recent acute illness. Patients affected by studied at the time of the discovery of their renal pathol-
ogy, and for this reason, they were not following anynephrotic syndrome were also excluded. In addition, the
selection procedure for controls involved checking for dietary regimen at that time. HD patients were advised
to restrict the intake of phosphate and potassium-richnormal renal function. None of the patients were taking
lipid-lowering drugs or antioxidant supplements. The foods and fluid when required. All control subjects were
free of prescribed drugs and were without dietary restric-drugs they were using included dihydropyridine calcium
channel blockers, clonidine, furosemide, vitamin D, and tions. Other demographic and clinical characteristics are
shown in Table 1.calcium carbonate. The etiology of renal failure was
Lucchi et al: Conjugated dienes in CRF 1697
Table 1. Demographic data, biochemical parameters and dietary assessment of control subjects and patients participating in the study
CRF
Healthy
controls CCr .10 mL/min CCr ,10 mL/min Hemodialysis
Subjects N 30 23 21 30
Age years 55.8613.6 56.3616.1 58.4615.3 58.8616.9
Total cholesterol mg/dL 209.7637.7 194.0646.5 183.4650.9 186.0641.7
HDL cholesterol mg/dL 51.0611.6 38.5612.4a 39.0611.1a 41.1614.1a
Triglycerides mg/dL 130.6674.0 130.9646.6 165.9671.1 149.0679.9
Albumin g/dL 4.2760.21 3.8660.38 3.9360.48 3.9760.49
Uric acid mg/dL 4.961.3 7.761.7a 7.761.8a 7.061.1a
Hemoglobin g/dL 14.561.4 10.862.3a 9.961.2a 10.961.8a
Ferritin ng/mL 80.3663.7 95.4679.2 120.26121.7 152.36140.3
PTH pg/mL 31627 128693a 1896112a 2536273a
Energy kcal/kg/day 37.3610.4 33.163.8 30.064.6a 36.067.8
Proteins g/kg/day 1.1860.26 1.0860.24 0.7960.17a 1.1760.43
Carbohydrates g/kg/day 4.7661.79 4.2860.63 3.9761.09 4.5561.11
Fats g/kg/day 1.5160.31 1.3360.22 1.1960.19a 1.4360.38
Abbreviations are: CRF, chronic renal failure; CCr, creatinine clearance; HDL, high-density lipoprotein; PTH, parathyroid hormone.
a P , 0.05 vs. controls
Samples and lipid extraction from the obtained ghost as illustrated for adipose tissue
previously in this article. All extracted lipids after beingBlood samples (20 mL) were taken from the antecubi-
dried under a flow of oxygen-free nitrogen gas weretal veins of controls and patients after an overnight fast.
stored at 2808C and were assayed for CD within 15 days.The blood was heparinized (10 IU/mL) and immediately
centrifuged at 2000 3 g for 10 minutes. Lipids were
High-pressure liquid chromatography analysis ofthen extracted from the resulting plasma and stored as
conjugated diene fatty acidspreviously reported [22, 23].
At the time of the analysis, the dry lipids residuesAdipose tissue (about 200 mg) was taken from the
were dissolved in cyclohexane, and 10 mg aliquots ofsubcutaneous fat of the forearm of CRF patients on
lipids were prepared as previously reported [22]. Freeconservative treatment at the time of arteriovenous fis-
fatty acids were obtained by saponification as describedtula institution and of HD patients during arteriovenous
in our previous article [31]. In every step, particular at-fistula revision. In control subjects, adipose tissue was
tention was paid to avoid heating or excessive expositiontaken from the forearm subcutaneous fat during surgical
to air and light in order to avoid oxidation of the samples.procedures for carpal tunnel syndrome. Adipose tissue
The solvents used, even in vapor form, can dissolve plas-samples were immediately washed with 0.9% sodium
tic. Consequently, plastic materials were not used inchloride, blotted, and flushed with oxygen-free nitrogen
those steps in which solvents were employed.gas. Lipids were then extracted as previously reported
Analysis of fatty acids was performed by using a high-[22, 23].
pressure liquid chromatography (HPLC) (Hewlett-Pack-Red blood cell membranes were prepared according
ard 1050M HPLC system), equipped with a Hewlett-to Burton, Ingold, and Thompson and Steck and Kant
Packard 1040 photodiode array detector, controlled by a[29, 30]. Red blood cells were washed three times resus-
Hewlett-Packard Chemstation software (Hewlett-Pack-pending the pellet in five volumes of phosphate-buffered
ard, Palo Alto, CA, USA). A reverse-phase C-18 columnsaline (centrifugation at 2000 3 g for 10 min at 48C).
(250 3 4 mm, 5 mm particles size) was used, and the mobileThe buffy coat was carefully aspirated from the surface
phase was acetonitrile/water/acetic acid (85:15:0.12, vol/of the pellet. Hemolysis was initiated by rapidly and
vol) with a flow rate of 1.5 mL/min. The first channel ofthoroughly mixing 1 mL of packed RBC with 40 mL of
the detector was set at 234 nm for measuring CD fatty5 mmol/L phosphate buffer, pH 8, previously refriger-
acids, whereas the second was set at 200 nm for measur-ated at 48C. The membranous ghosts were pelleted by
ing linoleic acid. Spectra (195 to 315 nm) of the eluatecentrifuging at 22,000 3 g for 10 minutes at 48C. After
were obtained every 1.28 seconds and were electronicallyremoval of the supernatant, the ghosts were resuspended
stored. Second derivative spectra were generated by us-in 40 mL of 2.5 mmol/L phosphate buffer, pH 8, pre-
ing the chemstation software of the HPLC system. Sim-viously refrigerated at 48C and centrifuged as previously
ple absorption and second derivative spectra of eachindicated. The ghosts were then washed a second time
chromatographic peak allowed us to identify those con-with an identical procedure using 1.25 mmol/L phosphate
buffer, pH 8, refrigerated at 48C. Lipids were extracted taining CDs [32]. Once the second derivative of the ab-
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sorption spectra is taken, CDs, if present, are revealed Microsoft Excel 5.0 (Microsoft Corporation, Redmond,
WA, USA).as two distinct signals, with a minim value at near 234
and 245 nm [33, 34]. Under these chromatographic condi-
tions, CD fatty acid hydroperoxides eluted at 4 minutes,
RESULTSCD18:3 at 7.6 minutes, CLA at 10.3 minutes, and CD20:3
Clinical and laboratory data of control subjects andat 11.6 minutes. Each of these peaks showed the typical
patients participating in the study are shown in Table 1.characteristics of CDs when subjected to second deriva-
In HD patients, the standard deviation of PTH is very hightive analysis [32]. Standard solution for CD fatty acid
because we included subjects with hyperparathyroidism inhydroperoxides was [9(S),10E,12Z]-9-hydroperoxyocta-
the study to evaluate the possible influence of PTH leveldecadien-1-oic acid purchased from Cascade Biochem
on the various parameters examined. The results of the(Berkshire, UK). The linoleic, linolenic, and eicosatrienoic
dietary assessment are also reported in Table 1. Significantacid were obtained from Sigma Chemicals (St. Louis, MO,
differences were found only in end-stage CRF patientsUSA). A mixture of standard CLA was obtained from
following a low-protein dietary regime. As reported inNU Chek Prep, (Elysian, MN, USA). CD18:3 and CD20:3
the Methods section, most of the patients with CCr .10were prepared by alkalinization from the corresponding
mL/min at the time of their enrollment in the study werefatty acid as previously described [31]. All of the other
not under dietary restriction, and thus, their dietary regi-reagents were of HPLC grade. Concentrations of CD fatty
men was comparable to controls.acid were expressed in ng/mg of lipids, and linoleic acid
Figure 1 shows the levels of CLA and its metabolitesin mg/mg of lipids.
together with CD fatty acid hydroperoxides, in lipids ex-
Other measurements tracted from plasma, adipose tissue, and RBC membranes
of healthy controls and patients groups. CLA is the mostParathyroid hormone (intact) levels were measured by
representative fatty acid with CD found in humans; itsa radioimmunoassay method, whereas all the other bio-
plasmatic and adipose tissue concentrations were signifi-chemical parameters were assayed by standard laboratory
cantly increased only in patients with CCr ,10 mL/mintests.
(Fig. 1A). Adipose tissue was obtained only in four pa-
Dietary intake tients with CCr .10 mL/min because it was taken at the
time of fistula placement, as described in the MethodsHabitual dietary intake was estimated by a trained dieti-
section. Therefore, data were omitted because of the smalltian by using the dietary history interview. Food photo-
sample number. CLA in RBC membranes was signifi-graphs were used to represent the estimated portion size.
cantly reduced in CRF patients with CCr .10 mL/min,All data regarding the foods were entered into a computer
and this reduction became more pronounced in end-stageprogram (Dietapro, Medimatica, S. Benedetto del Tronto,
CRF patients and HD patients. The behavior of CD18:3Italy) that is used for calculating the dietary variables
(Fig. 1B) and CD20:3 (Fig. 1C) was very similar to that(Table 1).
of CLA in RBC membranes, while no significant changes
Statistical analysis were found in plasma and adipose tissue. The concentra-
tions of CD fatty acid hydroperoxides (Fig. 1D) showedData were expressed as mean values 6 SD. One-way
no significant variations in plasma, adipose tissue, andanalysis of variance was used to test the differences among
RBC membranes of the various groups studied.the means of the groups. When differences were signifi-
To evaluate whether the variations in CLA contentcant, the Student–Newman–Keuls procedure was used for
might be due to a similar variation in the content of themultiple comparison among pairs of groups. Simple linear
non-CLA, we evaluated its concentration in the sameregression analysis was used to identify, for each of the CD
samples. No significant differences in linoleic acid contentfatty acid, the correlation between the levels in plasma,
in any of the groups studied were found (data not shown).adipose tissue, and RBC membranes. Multiple linear re-
Statistically significant correlations between the levelsgression analysis, using the stepwise elimination proce-
of CD fatty acids in plasma, adipose tissue, and RBCdure, was performed in order to assess the influence of
the various clinical and biochemical parameters reported membranes within each group are shown in Table 2. Inter-
estingly, where significant positive correlations were foundin Table 1 on CD fatty acid levels in plasma, adipose
tissue, and RBC membranes. Two-tailed tests of signifi- in the healthy control group, they were not confirmed in
any of the patient groups. Peculiarly, in CRF patients withcance were used, and a P value of less than 0.05 was
considered statistically significant. Statistical analyses CCr ,10 mL/min and HD patient groups, there was a
negative correlation between plasma CLA and RBC CLA,were performed by using the Statistical Package for the
Social Science (SPSS/PC; SPSS, Inc., Chicago, IL, USA). indicating a different incorporation of CLA into lipid
classes in these patients with respect to controls.Nonlinear regression analysis was performed by using the
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Fig. 1. Concentrations of (A) conjugated linoleic acid (CLA), (B) conjugated linolenic acid (CD18:3), (C) conjugated eicosatrienoic acid (CD20:3),
and (D) conjugated dienes (CD) fatty acid hydroperoxides in lipids extracted from plasma, adipose tissue, and red blood cell membranes of the
various groups studied. Symbols are: (h) controls; ( ) CRF patients with CCr .10 mL/min; ( ) CRF patients with CCr ,10 mL/min; (j)
hemodialyzed patients. *P , 0.05 between patients and controls. ##Adipose tissue data from patients with CCr .10 mL/min were omitted because
of the small sample number rendering statistical analysis not reliable.
Table 2. Significant correlations between the levels of the various CD fatty acids in plasma, adipose tissue and
red blood cell membranes evaluated by linear regression analysis
Healthy CRF CRF
controls CCr .10 mL/min CCr ,10 mL/min Hemodialysis
Variable 1 Variable 2 r P r P r P r P
Plasma CLA Adipose tissue CLA 0.61 0.047
Plasma CLA Red blood cells CLA 0.56 0.045 20.47 0.000 20.46 0.012
Plasma CD18:3 Red blood cells CD18:3 0.61 0.004
In Table 3, the results of the multiple regression analy- CD. In CRF patients, CCr was the only significant pre-
dictor variable for plasma CLA, RBC membrane CLA,ses are shown. All variable listed in Table 1, together
with linoleic acid, CCr, and dialytic age were considered and RBC membrane CD18:3. When the regression be-
tween plasma CLA and CCr in CRF patients was plotted,as predictor variables, while CLA, CD18:3, CD20:3, and
CD fatty acids hydroperoxides in the plasma, adipose it appeared to be nonlinear as shown in Figure 2. The
highest R2 was obtained using the exponential regression.tissue, and RBC were considered dependent variables.
CRF patients were analyzed as one group and were not In a previous article [23], we found that in CRF patients
with CCr .20 mL/min, the levels of plasma total CDsdivided into two groups with different CCr in order to
have a wide range of CCr within the group to evaluate were similar to that found in control subjects. This finding
was confirmed in the present study by measuring plasmathe possible influence of CCr on CD fatty acids better.
In the control group and HD patient group, none of the CLA. Therefore, we focused our attention on patients
with very advanced renal failure (Fig. 2).variables considered significantly influenced the level of
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Table 3. Results of multiple linear regression analysis
Predictor
Dependent variable variables Adjusted R2 Constant B Beta P
CRF patients Plasma CLA CCr 0.261 1504 213.6 20.53 0.000
Red blood cell CLA CCr 0.608 428.7 4.82 0.78 0.000
Red blood cell CD18:3 CCr 0.479 100.3 1.19 0.70 0.000
B represents the partial regression coefficient; Beta is the standardized regression coefficient and Constant is sometimes called intercept.
formation, or too low of an intake of CLA. Our results
also showed that CLA and its metabolites’ distribution
in humans mirrored that previously seen in rats [21],
with a preferential incorporation in neutral lipid reach
tissues such as adipose tissue.
One of the major results of the present study is that the
site distribution of CLA and its metabolites are altered in
CRF patients. As far as the CLA is concerned, the earli-
est alteration found during the progression of CRF is its
reduced incorporation in RBC membrane lipids (Fig. 1).
This alteration partly could be responsible for the accu-
mulation of CLA in the adipose tissue and for its increase
in the plasma of patients with end-stage CRF (Figs. 1
and 2). The accumulation of CLA in the adipose tissue
is not likely to be explained by an increased dietaryFig. 2. Relationship between plasma CLA and predicted CCr in the
CRF patients group. The continuous line represents the linear regres- intake of CLA, because of the lower consumption of
sion (y 5 214.23x 1 1514.5, R2 5 0.305). The dotted line represents
milk and dairy products by CRF patients. An alterationthe logarithmic regression [y 5 2317.9Ln(x) 1 2052.5, R2 5 0.442],
and the dashed line represents the exponential regression (y 5 in the intestinal flora of CRF patients with an increased
2292.8x20.2551, R2 5 0.490). production of CLA might be possible. Several bacterial
species involved in respiratory pathology are also capa-
ble of producing CLA in vitro [abstract; Jack et al, Clin
Sci 81(Suppl 25):S62, 1991].DISCUSSION
CD18:3 and CD20:3 were also found to be significantlyIn the present study, we confirm previous results [22]
reduced in RBC membrane lipids of CRF patients (Fig.showing that the major part of CD found in vivo is
1). As these CLA metabolites were not found signifi-represented by nonhydroperoxides, and consequently,
cantly increased in the adipose tissue of our patients, asthe measurement of total CD may not be used as a
it was for CLA, it is possible that a reduced metaboliza-marker of lipid peroxidation in vivo as used in the past
tion of CLA, through desaturation and elongation, was[2, 35].
present in CRF patients. The possible impaired CLAAs far as the nonhydroperoxides CD fatty acids are
metabolism, along with a different tissue and/or lipidconcerned, CLA is the most representative CD found
class distribution of CLA, may explain its increase inin humans. The National Academy of Sciences has
plasma and adipose tissue of end-stage CRF patients.pointed out that CLA is the only fatty acid that has
The finding of unchanged levels of linoleic acid in thebeen shown unequivocally to inhibit carcinogenesis in
different groups studied indicates that CLA has a differ-experimental animals [36]. Studies on humans are still
ent compartmentalization than its parent compound li-in their infancy. While it has been shown that dietary
noleic acid.CLA is absorbed and deposited in human tissues, to our
Whether changes in the CD fatty acid levels found inknowledge, the present study is the first report showing
renal failure may have clinical significance is difficult tothat CLA metabolites CD18:3 and CD20:3 produced by
be established at the present stage of our knowledge.desaturation and elongation reaction are also present in
However, experimental animal models clearly demon-human plasma and tissues. However, no CD20:4 (the
strated that CLA affects metabolic interconversion ofexpected main metabolite) was detected. The failure to
fatty acids in the liver [37]. Particularly, CLA modulatesdetect CD20:4 may be explained by either a high dietary
phospholipid arachidonic acid, competing with linoleicintake of linoleic acid, which shares desaturase and elon-
gase enzymes with CLA and thus competes for CD20:4 acid for D6 desaturase, the rate-limiting step in the con-
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